Intensive research on the oncophysiology of SCCHN has been conducted, however, epidermal growth factor receptor (EGFR) remains the sole druggable molecular target with meaningful benefit, other than immune-related pathways [2, 9–12]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.